Immatics N.V.
NASDAQ•IMTX
CEO: Dr. Harpreet Singh Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-12-12
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Contact Information
Market Cap
$1.33B
P/E (TTM)
-8.8
37
Dividend Yield
--
52W High
$12.41
52W Low
$3.30
52W Range
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Financial Dashboard
Q3 2025 Data
Revenue
$6.06M-89.74%
4-Quarter Trend
EPS
-$0.49+419.16%
4-Quarter Trend
FCF
-$53.52M+25.34%
4-Quarter Trend
2024 Annual Earnings Highlights
Key Highlights
Collaboration Revenue Surge Collaboration revenue reached €155.8M in 2024, up significantly from €54.0M in 2023, driven by Moderna agreement recognition.
Return to Profitability Achieved net profit of €15.2M in 2024, reversing prior year net loss of €94.6M; operating result improved to €(38.6M) loss.
Strong Cash Position Cash and equivalents totaled €236.7M as of year-end 2024, providing funding runway for at least next 12 months operations.
IMA203 Clinical Activity IMA203 showed 54% confirmed objective response rate (cORR) in advanced melanoma patients; median DOR 12.1 months.
Risk Factors
History of Operating Losses Company has history of operating losses (€589.5M accumulated deficit); expects continued losses funding R&D expansion efforts.
Material Internal Control Weakness Material weakness identified in DTA/DTL recognition led to restatement of 2022 and 2023 consolidated financial statements.
Need for Additional Capital Requires additional capital to fund operations; ability to raise funds depends on volatile financial, economic, and market conditions.
Clinical Trial Execution Risks Clinical trials face numerous risks including delays, high costs, patient recruitment challenges, and potential regulatory hurdles.
Outlook
IMA203 Phase 3 Trial Progress SUPRAME Phase 3 trial for IMA203 commenced December 2024; interim data analysis expected in 1Q 2026.
Regulatory Submission Target Targeting Biologics License Application (BLA) submission for IMA203 in 1Q 2027, aiming for market launch in 3Q 2027.
Pipeline Expansion Focus Expanding PRAME opportunity with IMA203CD8 in non-melanoma cancers and advancing TCER IMA401/IMA402 programs.
Manufacturing Facility Readiness New Houston GMP facility expected to commence GMP manufacturing of cell therapy products starting in 2025.
Peer Comparison
Revenue (TTM)
ARDX$398.23M
$109.23M
$93.54M
Gross Margin (Latest Quarter)
100.0%
100.0%
ARDX98.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| WVE | $2.46B | -18.5 | -75.6% | 8.2% |
| IMNM | $2.37B | -10.2 | -87.2% | 1.3% |
| SYRE | $1.93B | -16.1 | -31.2% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-53.4%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 26, 2026
EPS:-$0.48
|Revenue:-
Reports
All Years
Form 20-F - FY 2024
Period End: Dec 31, 2024|Filed: Mar 27, 2025|Revenue: $168.58M+188.6%|EPS: $0.15+111.7%BeatForm 20-F - FY 2023
Period End: Dec 31, 2023|Filed: Mar 21, 2024|Revenue: $58.41M-68.8%|EPS: $-1.30-318.2%MissForm 20-F - FY 2022
Period End: Dec 31, 2022|Filed: Mar 22, 2023|Revenue: $181.70M+397.2%|EPS: $0.58+136.4%BeatForm 20-F - FY 2021
Period End: Dec 31, 2021|Filed: Mar 23, 2022|Revenue: $41.11M+11.2%|EPS: $-1.79+68.4%BeatForm 20-F/A - FY 2020
Period End: Dec 31, 2020|Filed: Oct 28, 2021|Revenue: $38.32M+69.4%|EPS: $-5.86-856.0%MissForm 20-F - FY 2020
Period End: Dec 31, 2020|Filed: Mar 30, 2021|Refer to amended data